Evaluating Performance Portability with the CMS Heterogeneous Pixel Reconstruction code
Explore the source record for details and available documents.
Engineering topics
Publications and source records attributed to Hugo, G..
Explore the source record for details and available documents.
Deformable image registration has now been commercially available for several years, with solid performance in a number of sites and for several applications including contour and dose mapping. However, more complex applications have arisen, such as assessing response to radiation therapy over time, registering images pre- and post-surgery, and auto-segmentation from atlases. These applications require innovative registration algorithms to achieve accurate alignment. The goal of this session is to highlight emerging registration technology and these new applications. The state of the art in image registration will be presented from an engineering perspective. Translational clinical applications will also be discussed to tie these new registration approaches together with imaging and radiation therapy applications in specific diseases such as cervical and lung cancers. Learning Objectives: To understand developing techniques and algorithms in deformable image registration that are likely to translate into clinical tools in the near future. To understand emerging imaging and radiation therapy clinical applications that require such new registration algorithms. Research supported in part by the National Institutes of Health under award numbers P01CA059827, R01CA166119, and R01CA166703. Disclosures: Phillips Medical systems (Hugo), Roger Koch (Christensen) support, Varian Medical Systems (Brock), licensing agreements from Raysearch (Brock) and Varian (Hugo).; K. Brock, Licensing Agreement - RaySearch Laboratories. Research Funding - Varian Medical Systems; G. Hugo, Research grant from National Institutes of Health, award number R01CA166119.; G. Christensen, Research support from NIH grants CA166119 and CA166703 and a gift from Roger Koch. There are no conflicts of interest.
Purpose: To present a method to evaluate the dose mapping error introduced by the dose mapping process. In addition, apply the method to evaluate the dose mapping error introduced by the 4D dose calculation process implemented in a research version of commercial treatment planning system for a patient case. Methods: The average dose accumulated in a finite volume should be unchanged when the dose delivered to one anatomic instance of that volume is mapped to a different anatomic instance--provided that the tissue deformation between the anatomic instances is mass conserving. The average dose to a finite volume on image S is defined as d{sub S}=e{sub s}/m{sub S}, where e{sub S} is the energy deposited in the mass m{sub S} contained in the volume. Since mass and energy should be conserved, when d{sub S} is mapped to an image R(d{sub S{yields}R}=d{sub R}), the mean dose mapping error is defined as {Delta}d{sub m}=|d{sub R}-d{sub S}|=|e{sub R}/m{sub R}-e{sub S}/m{sub S}|, where the e{sub R} and e{sub S} are integral doses (energy deposited), and m{sub R} and m{sub S} are the masses within the region of interest (ROI) on image R and the corresponding ROI on image S, where R and S are the two anatomic instances from the same patient. Alternatively, application of simple differential propagation yields the differential dose mapping error, {Delta}d{sub d}=|({partial_derivative}d/{partial_derivative}e)*{Delta}e+({partial_derivative}d/{partial_derivative}m)*{Delta}m|=|((e{sub S}-e{sub R})/m{sub R})-((m{sub S}-m{sub R})/m{sub R}{sup 2})*e{sub R}|={alpha}|d{sub R}-d{sub S}| with {alpha}=m{sub S}/m{sub R}. A 4D treatment plan on a ten-phase 4D-CT lung patient is used to demonstrate the dose mapping error evaluations for a patient case, in which the accumulated dose, D{sub R}={Sigma}{sub S=0}{sup 9}d{sub S{yields}R}, and associated error values ({Delta}D{sub m} and {Delta}D{sub d}) are calculated for a uniformly spaced set of ROIs. Results: For the single sample patient dose distribution, the average accumulated differential dose mapping error is 4.3%, the average absolute differential dose mapping error is 10.8%, and the average accumulated mean dose mapping error is 5.0%. Accumulated differential dose mapping errors within the gross tumor volume (GTV) and planning target volume (PTV) are lower, 0.73% and 2.33%, respectively. Conclusions: A method has been presented to evaluate the dose mapping error introduced by the dose mapping process. This method has been applied to evaluate the 4D dose calculation process implemented in a commercial treatment planning system. The method could potentially be developed as a fully-automatic QA method in image guided adaptive radiation therapy (IGART).